Immunocore Holdings plc American Depositary Receipt (IMCR)
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Morgan Stanley downgraded Amicus Therapeutics Inc FOLD. Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd.
All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy
Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for December 12th
NBBK, OMCL, ZIM, IMCR and ULS have been added to the Zacks Rank #1 (Strong Buy) List on December 12, 2024.
Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 112.8% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
New Strong Buy Stocks for November 26th
ZIM, MNDY, RSI, IMCR and ULS have been added to the Zacks Rank #1 (Strong Buy) List on November 26, 2024.
Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 112.6% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Immunocore (IMCR) Upgraded to Buy: Here's Why
Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Immunocore: Pipeline Expands HLA Tumor Targeting Beyond Kimmtrak
In Q2 of 2024, sales of Kimmtrak were $75 million, which was a year-over-year increase of 32%. Two expansion opportunities are possible for Kimmtrak, which are using it as an adjuvant for uveal melanoma and 2nd-line advanced cutaneous melanoma. Data from the phase 1/2 study, using brenetafusp for the treatment of patients with high-grade serous ovarian cancer, to be presented as a poster at the upcoming ESMO 2024 conference.
Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal
Immunocore Holdings is a biotech company with a promising revenue trajectory in 2024, driven by its leading product, KIMMTRAK. IMCR has a diverse pipeline with potential value drivers like IMC-F106C for cutaneous melanoma and IMC-M113V for HIV. The main risks stem from the Company's heavy reliance on KIMMTRAK and potential clinical trial failures for other pipeline drugs, such as IMC-F106C and IMC-M113V.
Immunocore Holdings plc (IMCR) Q2 2024 Earnings Call Transcript
Immunocore Holdings plc (NASDAQ:IMCR ) Q2 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Clayton Robertson - Head of Investor Relations Bahija Jallal - CEO Brian Di Donato - CFO and Head of Strategy Ralph Torbay - Head, Commercial David Berman - Head, R&D Conference Call Participants Clayton Robertson - Head of Investor Relations Bahija Jallal - CEO Brian Di Donato - CFO and Head of Strategy Ralph Torbay - Head, Commercial David Berman - Head, R&D Mohammed Dar - CMO Michael Yee - Jefferies Elias Lenard - JPMorgan Tyler Van - TD Cowen Eric Schmidt - Cantor Fitzgerald Michael Schmidt - Guggenheim Jack Allen - Baird Justin Zelin - BTIG Jonathan Chang - Leerink Securities Ahu Demir - Ladenburg Thalmann Avantika Joshi - Mizuho Naureen Quibria - Capital One Securities Rajan Sharma - Goldman Sachs Ethan Markowski - Needham & Company Operator Welcome to the Immunocore Conference Call and Webcast. At this time, all participants are in a listen-only mode.
3 Small-Cap Stocks with Significant Growth Potential
The Federal Reserve seems prepared to cut interest rates, perhaps by its next meeting in September. That's one reason that institutional dollars are starting to rotate into small-cap growth stocks.
